Caidya and Simbec-Orion Combine to Create Global Specialty CRO Platform Spanning Early-Phase Research Through Late-Stage Clinical Development
Caidya has announced a strategic combination with Simbec-Orion, marking a significant step in the evolution of both organizations as they seek to deliver a more integrated approach to clinical research and drug development services. The combination creates a specialty contract research organization (CRO) platform designed to bridge the gap between early scientific discovery and global clinical execution, enabling biopharmaceutical companies to advance innovative therapies more efficiently from first-in-human studies through regulatory registration.
The newly combined organization brings together complementary expertise, expanded geographic reach, and broader therapeutic capabilities while maintaining the specialist focus, operational agility, and client-centered approach that have defined both companies. By integrating their respective strengths, Caidya and Simbec-Orion aim to provide biotechnology and pharmaceutical sponsors with a seamless development partner capable of supporting increasingly complex global clinical programs.
Building an End-to-End Clinical Development Partner
Drug development has become increasingly complex as biotechnology companies pursue innovative therapies across multiple therapeutic areas, often conducting multinational clinical trials that require specialized scientific expertise, regulatory knowledge, and operational excellence.
Recognizing these evolving industry demands, Caidya and Simbec-Orion have joined forces to create a more comprehensive CRO platform capable of supporting every major stage of clinical development. The strategic combination is intended to eliminate many of the operational transitions that sponsors traditionally experience when moving from early-stage clinical studies into larger global trials.
Rather than relying on multiple service providers throughout development, sponsors will have access to a continuous clinical development pathway that extends from First-in-Human studies through Phase III trials and regulatory submissions. This integrated model is designed to preserve institutional knowledge, improve communication between development teams, and maintain consistency throughout the lifecycle of a clinical program.
The organizations believe this continuity can help accelerate decision-making, reduce operational complexity, and improve overall trial execution while maintaining accountability at every stage.
Combining Complementary Expertise
One of the defining features of the combination is the highly complementary nature of each company’s capabilities.
Caidya has established itself as a global CRO with broad operational capabilities supporting complex international clinical trials across multiple therapeutic areas. Its infrastructure spans major pharmaceutical markets in North America, Europe, Asia-Pacific, and China, providing sponsors with extensive experience managing multinational development programs.
Simbec-Orion, meanwhile, has built a strong reputation over nearly five decades as a specialist CRO with particular expertise in early-phase clinical pharmacology, oncology, and rare disease research. The company has become well known for supporting biotechnology innovators during the critical early stages of drug development while also conducting later-stage clinical trials for complex therapeutic programs.
Together, these complementary strengths create a development organization capable of supporting sponsors from the earliest scientific evaluations through pivotal registration studies without requiring transitions between different CRO partners.
Expanding Global Reach
The strategic combination significantly strengthens the geographic footprint of both organizations.
The integrated company will maintain established operations across:
- Europe
- North America
- Latin America
- Asia-Pacific
- China
This expanded international presence enables sponsors to conduct cross-border clinical trials using a single development partner while benefiting from regional expertise and local regulatory knowledge.
For Caidya, the transaction substantially expands its European capabilities through Simbec-Orion’s long-established operations and extensive relationships across the European biotechnology ecosystem.
Conversely, Simbec-Orion gains broader access to the United States and Asian clinical research markets through Caidya’s existing global infrastructure.
The enhanced international presence is expected to be particularly valuable as biotechnology innovation becomes increasingly global, with therapies frequently being developed through collaborations spanning Europe, North America, and Asia.
Strengthening Early-Phase Development
A key strategic advantage created through the combination is the addition of Simbec-Orion’s highly regarded early-phase clinical pharmacology capabilities.
Among its most significant assets is a dedicated 48-bed Phase I Clinical Pharmacology Unit, recognized as one of Europe’s leading facilities for first-in-human clinical studies.
The unit enables sponsors to conduct:
- First-in-Human studies
- Healthy volunteer studies
- Patient-based early clinical trials
- Dose-escalation studies
- Clinical pharmacology research
By integrating these capabilities into Caidya’s broader clinical platform, the combined organization offers sponsors a continuous pathway that begins with early safety and pharmacokinetic evaluation and extends through late-stage registration trials.
Maintaining a single CRO throughout development helps preserve scientific knowledge generated during early studies while minimizing operational disruptions that can occur when transferring programs between organizations.
Supporting Complex Therapeutic Areas
The combined organization will place particular emphasis on therapeutic areas requiring specialized expertise and sophisticated operational management.
Simbec-Orion contributes deep experience in:
- Oncology
- Rare diseases
- Clinical pharmacology
These capabilities complement Caidya’s broader global therapeutic expertise, creating an organization well positioned to support increasingly complex development programs involving precision medicine, targeted therapies, and innovative biologics.
Rare disease and oncology studies often involve multinational recruitment strategies, specialized clinical sites, and intricate regulatory requirements. By combining scientific knowledge with expanded global operational capabilities, the organization aims to simplify execution for sponsors developing treatments in these challenging therapeutic areas.
Addressing Cross-Border Innovation
One of the major trends influencing today’s pharmaceutical industry is the growing international nature of drug development.
Scientific innovation increasingly flows between North America, Europe, and Asia, with biotechnology companies frequently licensing assets, conducting multinational trials, and pursuing simultaneous regulatory approvals across multiple regions.
According to company leadership, the newly combined organization is specifically positioned to support this evolving landscape by providing integrated expertise across the world’s leading clinical research markets.
Its global infrastructure allows sponsors to navigate varying regulatory environments while coordinating multinational development programs through a unified operational framework.
Leadership Highlights Strategic Vision
Barbara Lopez Kunz, Chief Executive Officer of Caidya, described the strategic combination as an important milestone in expanding the company’s ability to serve innovative biopharmaceutical clients.
She explained that integrating Simbec-Orion’s European presence and early-phase expertise with Caidya’s established global platform creates a more comprehensive development partner capable of supporting programs from First-in-Human studies through regulatory approval.
According to Lopez Kunz, the combined organization is particularly well equipped to help sponsors navigate the increasingly complex intersection of scientific innovation, operational execution, and global clinical development.
Shared Culture and Client-Centered Approach
Fabrice Chartier, Chief Executive Officer of Simbec-Orion, emphasized that the two organizations share similar cultures focused on collaboration, responsiveness, and close relationships with clients.
He noted that while the combined company significantly expands its global capabilities, it intends to preserve the personalized service typically associated with specialist CROs.
Chartier highlighted that Simbec-Orion’s clients will benefit from expanded access to the United States and Asian markets, while Caidya clients gain stronger European capabilities and enhanced Phase I clinical pharmacology expertise.
He also expressed confidence that combining the strengths of both organizations creates a more complete development partner capable of addressing the evolving needs of modern drug development.
Supporting Global Biopharmaceutical Growth
Dr. Lingshi Tan, Executive Chairman of Caidya’s Board, highlighted the strategic importance of integrating Simbec-Orion’s expertise with Caidya’s international clinical infrastructure.
He noted that Simbec-Orion has earned a strong reputation for excellence in early-stage research and navigating complex European regulatory environments.
By combining those strengths with Caidya’s global therapeutic expertise and operational scale, the organization becomes better positioned to support the expanding international exchange of biotechnology innovation among the United States, Europe, and Asia.
A New Chapter for Simbec-Orion
The transaction also marks an important milestone for private equity firm CBPE, which has supported Simbec-Orion’s growth since 2019.
Anand Jain, Partner at CBPE and Chairman of Simbec-Orion, stated that significant investments have been made in both personnel and digital transformation initiatives during CBPE’s ownership.
He described the strategic combination with Caidya as the ideal next phase for Simbec-Orion’s continued growth, benefiting employees, clients, and the broader organization.
Jain added that sponsors will gain access to an integrated development model that enables programs to progress from First-in-Human studies through registration while maintaining continuity with an experienced and trusted research partner.
Leadership Structure Going Forward
Following completion of the strategic combination, the combined organization will operate under the leadership of Barbara Lopez Kunz, who will continue serving as Chief Executive Officer.
Fabrice Chartier will remain responsible for leading Simbec-Orion’s operations within the integrated organization, helping ensure continuity for existing clients while supporting future growth initiatives.
This leadership structure is intended to preserve the strengths of both companies while enabling closer collaboration across their expanded global network.
Creating a More Integrated CRO Platform
The combination of Caidya and Simbec-Orion reflects broader trends within the clinical research industry, where sponsors increasingly seek integrated development partners capable of delivering specialized scientific expertise alongside global operational execution.
By combining early-phase clinical pharmacology, therapeutic specialization, multinational trial management, and expanded geographic coverage, the newly formed organization aims to offer biotechnology and pharmaceutical companies a seamless clinical development experience from discovery through commercialization.
As global drug development continues to become more scientifically sophisticated and internationally connected, the combined company believes its integrated platform will help sponsors accelerate innovation while maintaining the focus, speed, accountability, and collaborative partnerships required to bring life-changing therapies to patients worldwide.
About Caidya
Caidya is a global CRO partner dedicated to helping biopharma innovators navigate the complexities of drug development with greater speed, certainty, and confidence. We specialize in the execution of complex clinical trials, including challenging therapeutic areas, innovative study designs, rare patient populations, and cross-border programs. We partner closely with sponsors to advance breakthrough therapies for patients with unmet medical needs worldwide.
With a strategic footprint across the Americas, Europe, and Asia-Pacific, including deep expertise in China, Caidya combines global reach with local knowledge to support regional and global studies. We work as an extension of our clients to overcome complexity, reduce risk, and generate the high-quality data needed to advance critical therapies.
About Simbec-Orion
Headquartered in the UK, Simbec-Orion is an experienced, technology-enabled, global Contract Research Organisation (CRO) specialising in clinical pharmacology, oncology, and rare diseases. With over five decades of experience, Simbec-Orion provides clinical trial expertise to a wide range of small to mid-sized biotech and pharmaceutical partners around the world.
